Control of syngeneic tumor growth by activation of CD8+ T cells: Efficacy is limited by migration away from the site and induction of nonresponsiveness

Journal of Immunology

Volumn 162, Issue 5, 1999, Pages 2858-2866

  Shrikant, Protul ^a   Mescher, Matthew F ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; INTERLEUKIN 4; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CLONAL ANERGY; CONTROLLED STUDY; GENETIC TRANSFECTION; LYMPH NODE; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL CULTURE; TUMOR GROWTH;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; H-2 ANTIGENS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; OVALBUMIN; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033104693     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Boon, T., J.-C. Cerottini, B. Van den Eynde, P. van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12: 337.
2. Pardoll, D.M. 1994. Tumor antigens for the 1990's. Nature 369:357.
3. Slingluff, C., D. Hunt, and V. Engelhard. 1994. Direct analysis of tumor-associated peptides. Curr. Opin. Immunol. 6:733.
4. Dye, E., and R. North. 1981. T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases. J. Exp. Med. 154:1033.
5. Cheever, M., P. Greenberg, and A. Fefer. 1981. Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially sensitized in vivo and in vitro and nonspecifically expanded by culture with interleukin 2. J. Immunol. 126:1318.
6. Dailey, M., E. Pillemer, and I. Weissman. 1982. Protection against syngeneic lymphoma by a long-lived cytotoxic T-cell clone. Proc. Natl. Acad. Sci. USA 79:5384.
7. Rosenstein, M., T. Eberlein, and S. Rosenberg. 1984. Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations. J. Immunol. 132:2115.
8. Hom, S., S. Topalian, T. Simonis, M. Mancini, and S. Rosenberg. 1991. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction. J. Immunother. 10:153.
9. + T-cell clones from regional lymph nodes of melanoma patients. Int. J. Cancer 51:218.
10. Schendel, D. J., R. Oberneder, C. S. Falk, P. Jantzer, S. Kressenstein, B. Maget, A. Hofstetter, G. Riethmuller, and E. Nossner. 1997. Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy. J. Mol. Med. 75:400.
11. Kearney, E., K. Pape, D. Loh, and M. Jenkins. 1994. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1:327.
12. + memory T cells in virus-infected hosts. J. Exp. Med. 183:1367.
13. + T cells during an acute virus infection. Immunity 8:167.
14. + T cells upon in vivo stimulation with allogeneic tumor. J. Immunol. 159:650.
15. Murali-Krishna, K., J. D. Altman, M. Suresh, D. J. D. Sourdive, A. J. Zajac, J. D. Miller, J. Slansky, and R. Ahmed. 1998. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8:177.
16. Moore, M., F. Carbone, and M. Bevan. 1988. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54:777.
17. + cytotoxic T lymphocyte responses. J. Immunol. 148:2357.
18. Zhou, F., B. T. Rouse, and L. Huang. 1992. Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: a model study. Cancer Res. 52:6287.
19. Fenton, R. G., D. D. Taub, L. W. Kwak, M. R. Smith, and D. L. Longo. 1993. Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J. Natl. Cancer Inst. 85:1294.
20. + T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res. 54:4155.
21. Porgador, A., D. Snyder, and E. Gilboa. 1996. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156:2918.
22. Brossart, P., A. W. Goldrath, E. A. Butz, S. Martin, and M. J. Bevan. 1997. Virus mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL activity. J. Immunol. 158:3270.
23. Hogquist, K., S. Jameson, W. Heath, J. Howard, M. Bevan, and F. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76:17.
24. Rotzschke, O., K. Falk, S. Stevanovic, G. Jung, P. Walden, and H.-G. Rammensee. 1991. Exact prediction of a natural T cell epitope. Eur. J. Immunol. 21:2891.
25. Vallera, D. A., P. A. Taylor, S. L. Aukerman, and B. R. Blazar. 1993. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2. Cancer Res. 53:4273.
26. Chen, L., P. McGowan, S. Ashe, J. Johnston, Y. Li, I. Hellstrom, and K. E. Hellstrom. 1994. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179:523.
27. Zaleski, M., and J. Klein. 1978. Genetic control of the immune response to Thy-1 antigens. Immunol. Rev. 38:120.
28. Huang, A. Y. C., A. T. Bruce, D. M. Pardoll, and H. I. Levitsky. 1996. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo. J. Exp. Med. 183:769.
29. Bevan, M. J. 1976. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143:1283.
30. van Seventer, G., Y. Shimizu, K. Horgan, and S. Shaw. 1990. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J. Immunol. 144:4579.
31. Kuhlman, P., V. Moy, B. Lollo, and A. Brian. 1991. The accessory function of murine ICAM-1 in T lymphocyte activation: contributions of adhesion and coactivation. J. Immunol. 146:1773.
32. Vermes, I., C. Haanen, H. Steffens-Nakken, and C. Reutelingsperger. 1995. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J. Immunol. Methods 184:39.
33. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
34. + T cell: receptor-dependent cytolysis in the absence of interleukin-2 production. Science 251:1228.
35. Jenkins, M., and R. Schwartz. 1987. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165:302.
36. Quill, H., and R. Schwartz. 1987. Stimulation of normal inducer T cell clones with antigen presented by purified Ia molecules in planar lipid membranes: specific induction of a long-lived state of proliferative non-responsiveness. J. Immunol. 138:3704.
37. Mueller, D., M. Jenkins, and R. Schwartz. 1989. Clonal expansion vs functional clonal inactivation. Annu. Rev. Immunol. 7:445.
38. Rocha, B., and H. von Boehmer. 1991. Peripheral selection of the T cell repertoire. Science 251:1225.
39. + T cells. J. Immunol. 151:2355.
40. Kyburz, D., P. Aichele, D. Speiser, H. Hengartner, R. Zinkernagel, and H. Pircher. 1993. T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides. Eur. J. Immunol. 23:1956.
41. + T cells induces functional but non-proliferative T cells in vivo. Immunology 83:333.
42. + T cells. J. Immunol. 154: 6306.